Opportunities
Search

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

Buyer: AOK Rheinland/Hamburg - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-08-05

This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and career development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs. This Funding Opportunity Announcement (FOA) allows support of [trainees] as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

The Flood Mitigation Assistance (FMA) grant program makes federal funds available to states, U.S. territories, federally recognized tribal governments, and local governments to reduce or eliminate the risk of repetitive flood damage to buildings and structures insured under the National Flood Insurance Program (NFIP) in participating communities. FMA funds a variety of flood mitigation activities that are designed to reduce flood risk to policyholders in an effort to reduce the NFIP’s financial exposure.Applicants can submit applications for this funding opportunity through FEMA Grants Outcomes (GO). Access the system at https://go.fema.gov/

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award, a product-driven award mechanism, intends to support the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP strategic goals. Products can be tangible items, such as drugs or devices, or can be knowledge products, such as clinical decision-making tools or practice guidelines. Products in development should address or have dual purpose potential for the health care needs of military Service Members, Veterans and their Families.Distinctive Features: For the PRMRP Technology/Therapeutic Development Award, the program expects the research proposed will take an already established proof-of-concept or prototype through the final stages of preclinical development. The PRMRP also expects that the research outcome will be a regulatory filing or translation of findings into clinical practice, as applicable.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $67.2M to fund approximately 12 Technology/Therapeutic Development Award applications with total cost caps of $5.6M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awar...

Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Impact Award supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research, and insights from the real-world environment, to foster clinical applicability. The Impact Award intends to translate the fundamental understanding of underlying mechanisms toward solutions that have the potential for major near-term impact for patients and clear alignment to one of the congressionally directed FY26 PRMRP topic areas and one of the FY26 PRMRP portfolio-specific strategic goals.Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI’s organization will submit a pre-application, but all PIs’ organizations will need to submit full applications. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $32.0M to fund approximately 10 Impact Award applications with total cost caps of $2.8M for the Single PI Option, or $3.6M for the Partnering PI Option. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awar...

Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.